August 2024 – schizophrenia

Aug 30 2024

Neurocrine reports mixed results on schizophrenia therapy in mid-stage trial

by Clinical Editor

No Comments

Neurocrine Biosciences said the lowest dose of an experimental pill for schizophrenia reduced psychosis reported by patients in a mid-stage study.

Aug 30 2024

Uncategorized

Javed Akhtar compares religious obsession to ‘schizophrenia’

by Clinical Editor

No Comments

Renowned lyricist Javed Akhtar recently expressed his views on the intersection of religion and intellect. He said that all religions, without exception, belong to the “dark ages.” The 77-year-old …

Aug 29 2024

Uncategorized

Neurocrine reports positive data from Phase II schizophrenia treatment trial

by Clinical Editor

No Comments

Neurocrine Biosciences has reported positive top-line results from its Phase II clinical study of NBI-1117568, an investigational oral treatment for schizophrenia. Named NBI-‘568-SCZ2028, the study …

Aug 29 2024

Uncategorized

Neurocrine Shares Drop 20% Despite Meeting Primary Endpoint in Mid-Stage Schizophrenia Trial

by Clinical Editor

No Comments

Neurocrine Biosciences’ potential competitor to Bristol Myers Squibb’s KarXT improved symptoms of schizophrenia in a Phase II trial, but only at the low dose tested.

Aug 28 2024

Uncategorized

Neurocrine stock dips even as schizophrenia drug meets main goal in study

by Clinical Editor

No Comments

Neurocrine Biosciences (NASDAQ:NBIX) said on Wednesday its experimental oral drug (NBI-1117568) to treat adults with schizophrenia met the primary goal in a mid-stage study. The NBI-‘568-SCZ2028 …

Aug 28 2024

Uncategorized

Neurocrine’s schizophrenia drug meets main goal in mid-stage study

by Clinical Editor

No Comments

Neurocrine Biosciences said on Wednesday its experimental drug to treat adults with schizophrenia met the main goal in a mid-stage study. A 20 milligram dose of the drug candidate, NBI-1117568,...

Aug 27 2024

Uncategorized

Schizophrenia Market: RISVAN’s Approval Has Sparked a Competitive Race Among Pharmaceutical Companies | DelveInsight

by Clinical Editor

No Comments

RISVAN has the potential to become a blockbuster drug. LAS VEGAS, Aug. 26, 2024 /PRNewswire/ — Schizophrenia is a severe mental illness affecting about 1% of Americans, cognitive functions, emotional...

Aug 27 2024

Uncategorized

No spike in schizophrenia, other diagnoses among dementia patients after feds crack down on antipsychotic use: study

by Clinical Editor

No Comments

Credit: Nathan Griffith/Getty Images Federal policies designed to reduce use of antipsychotic medications in nursing homes did not lead to clinically significantly higher rates of schizophrenia …

Aug 25 2024

Uncategorized